Estrogen receptor β potentiates the antiproliferative effect of raloxifene and affects the cell migration and invasion in HCT-116 colon cancer cells

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 7, 2012, Pages 1091-1103

  Tu, Zhenzhen ^a   Ma, Yuxiang ^a   Tian, Junmei ^a   Li, Hui ^a   Akers, Walter ^b   Achilefu, Samuel ^b   Gu, Yueqing ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

Apoptosis; Colon cancer; Estrogen receptor ; Xenograft

Indexed keywords

ADENOVIRUS VECTOR; ESTROGEN RECEPTOR BETA; RALOXIFENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER INHIBITION; CANCER INVASION; CELL STRAIN HCT116; COLON CANCER; COLONY FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ESTROGEN RECEPTOR BETA GENE; FEMALE; GENE OVEREXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MIGRATION INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR GENE; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLON; COLONIC NEOPLASMS; DEPENDOVIRUS; ESTROGEN RECEPTOR BETA; GENETIC VECTORS; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; RALOXIFENE; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864375438     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1145-3     Document Type: Article

References (38)

1. Bardin A, Boulle N, Lazennec G, Vignon F, Pujol P (2004) Loss of ERβ expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer 11:537-551 (Pubitemid 39331282)
2. Brossard D, Kihe LE, Clément M, Sebbahi W, Khalid M, Roussakis C, Rault S (2010) Synthesis of bile acid derivatives and in vitro cytotoxic activity with pro-apoptotic process on multiple myeloma (KMS-11), glioblastoma multiforme (GBM), and colonic carcinoma (HCT-116) human cell lines. Eur J Med Chem 45:2912-2918
3. Bryant HU, Glasebrook AL, Yang NN, Sato M (1999) An estrogen receptor basis for raloxifene action in bone. J Steroid Biochem Mol Biol 69:37-44 (Pubitemid 29305524)
4. Campbell-Thompson M, Lynch IJ, Bhardwaj B (2001) Expression of estrogen receptor (ER) subtypes and ERβ isoforms in colon cancer. Cancer Res 61:632-640 (Pubitemid 32128626)
5. Castiglione F, Taddei A, Degl'innocenti DR, Buccoliero AM, Bechi P, Garbini F, Gheri CF, Moncini D, Cavallina G, Marascio L, Freschi G, Taddei GL (2008) Expression of estrogen receptors [beta] in colon cancer progression. Diagn Mol Pathol 17:231-236
6. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation (MORE). JAMA 281:2189-2197 (Pubitemid 29275701)
7. Deng H, Makizumi R, Ravikumar TS, Dong H, Yang W, Yang WL (2007) Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT- 116 cells. Exp Cell Res 313:1033-1044 (Pubitemid 46273448)
8. Edvardsson K, Ström A, Jonsson P, Gustafsson JÅ, Williams C (2011) Estrogen receptor beta induces antiinflammatory and antitumorigenic networks in colon cancer cells. Mol Endocrinol 25:1-11
9. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. JAMA 282:637-645 (Pubitemid 29384151)
10. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW (2000) Selective loss of estrogen receptor β in malignant human colon. Cancer Res 60:245-248 (Pubitemid 30070743)
11. Grodstein F, Newcomb PA, Stampfer MJ (1999) Postmenopausal hormone therapy and the risk of colorectal cancer: a review and metaanalysis. Am J Med 106:574-582 (Pubitemid 29231110)
12. Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, Ström A, Gustafsson JA (2009) Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells. Cancer Res 69:6100-6106
13. Hsu HH, Cheng SF, Wu CC, Chu CH, Weng YJ, Lin CS, Lee SD, Wu HC, Huang CY, Kuo WW (2006) Apoptotic effects of overexpressed estrogen receptor-beta on Loffo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. Chin J Physiol 49:110-116
14. Janakiram NB, Steele VE, Rao CV (2009) Estrogen receptor-β as a potential target for colon cancer prevention: chemoprevention of azoxymethane- induced colon carcinogenesis by raloxifene in F344 rats. Cancer Prev Res 2:52-59
15. Jassam N, Bell SM, Speirs V, Quirke P (2005) Loss of expression of oestrogen receptor β in colon cancer and its association with Dukes' staging. Oncol Rep 14:17-21
16. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008) Cancer statistics. CA Cancer J Clin 58:71-96
17. Jooss K, Chirmule N (2003) Immunity to adenovirus and adeno-associated viral vectors: Implications for gene therapy. Gene Ther 10:955-963 (Pubitemid 36722430)
18. Katznellenbogen BS, Katznellenbogen JA (2002) Defining the "S" in SERMs. Science 295:2380-2381
19. Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, Sotiropoulou-Bonikou G, Papavassiliou AG (2003) Oestrogen receptor beta (ERβ) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 39:1251-1258 (Pubitemid 36579196)
20. Kuiper GGJM, Lemmen JG, Carlsson B (1998) Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor-β. Endocrinology 3:4252-4263 (Pubitemid 28513713)
21. Lee DE, Lee KW, Jung SK, Lee EJ, Hwang JA, Lim TG, Kim BY, Bode AM, Lee HJ, Dong Z (2011) 6,7,4'-Trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2. Carcinogenesis 32:629-635
22. Levy N, Tatomer D, Herber CB, Zhao X, Tang H, Sargeant T, Ball LJ, Summers J, Speed TP, Leitman DC (2008) Differential regulation of native estrogen receptor-regulatory elements by estrodiol, tamoxifen, and raloxifene. Mol Endocrinol 22:287-303 (Pubitemid 351185932)
23. Martineti V, Picariello L, Tognarini I, Sala SC, Gozzini A, Azzari C, Mavilia C, Tanini A, Falchetti A, Fiorelli G, Tonelli F, Brandi ML (2005) ERβ is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr Relat Cancer 12:455-469 (Pubitemid 40896459)
24. Mayo Clinic Women's HealthSource (2006) Raloxifene works as well as tamoxifen in preventing invasive breast cancer. Mayo Clin Women's HealthSource 10:3
25. Morishima S, Shibata MA, Ohmichi M, Otsuki Y (2008) Raloxifene, a selective estrogen receptor modulator, induces mitochondriamediated apoptosis in human endometrial carcinoma cells. Med Mol Morphol 4:132-138
26. Motylewska E, Stasikowska O, Meiej-Mucha G (2009) The inhibitory effect of diarylpropionitrile, a selective agonist of estrogen receptor beta, on the growth of MC38 colon cancer line. Cancer Lett 276:68-73
27. Ning T, Yan X, Lu ZJ, Wang GP, Zhang NG, Yang JL, Jiang SS, Wu Y, Yang L, Guan YS, Luo F (2009) Gene therapy with the angiogenesis inhibitor endostatin in an orthotopic lung cancer murine model. Hum Gene Ther 20:103-111
28. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108 (Pubitemid 40372904)
29. Parmar H, Young P, Emerman JT, Neve RM, Dairkee S, Cunha GR (2002) A novel method for growing human breast epithelium in vivo using mouse and human mammary Wbroblasts. Endocrinology 143:4886-4896 (Pubitemid 35397628)
30. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64:423-428 (Pubitemid 38114127)
31. Pasi AJ, Robert JM (2000) Chemoprevention of colorectal cancer. New Engl J Med 342:1960-1968
32. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288:321-333 (Pubitemid 34761611)
33. Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, Okaji Y, Nishikawa T, Shuno Y, Hongo K, Hiyoshi M, Kaneko M, Kitayama J, Takahashi K, Nagawa H (2010) Chloroquine potentiates the anticancer effect of 5-Xuorouracil on colon cancer cells. BMC Cancer 10:370
34. Schrag D (2004) The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med 351:317-319 (Pubitemid 38944397)
35. Terranova VP, Hujanen ES, Loeb DM, Martin GR, Thornburg L, Glushko V (1986) Use of a reconstituted basement membrane to measure cell invasiveness and select for highly invasive tumor cells. Proc Natl Acad Sci USA 83:465-469 (Pubitemid 16080034)
36. Waliszewski P, Blaszczyk M, Wolinska-Witort E, Drews M, Snochowski M, Hurst RE (1997) Molecular study of sex steroid receptor gene expression in human colon and in colorectal carcinomas. J Surg Oncol 64:3-11 (Pubitemid 27082000)
37. Wang X, Wang Q, Ives KL, Evers BM (2006) Curcumin inhibits neurotensin- mediated interleukin-8 production and migration of HCT116 human colon cancer cells. Clin Cancer Res 12:5346-5355 (Pubitemid 44497247)
38. Wickerham DL, Costantino JP, Vogel VG, Cronin WM, Cecchini RS, Ford LG, Wolmark N (2009) The use of tamoxifen and raloxifene for the prevention of breast cancer. Recent Results Cancer Res 181:113-119